ASCO 2013: Discover the Data
We're presenting important new findings on unapproved and investigational medicines at ASCO 2013.
On May 14, 2013, the FDA approved a personalized medicine for people newly diagnosed with a genetically distinct type of metastatic Non-Small Cell Lung Cancer (NSCLC).
Genentech is committed to ensuring price is not a barrier to access for patients. Learn about our programs.
Celebrating the Discovery of the Structure of DNA
We built an iPad app that turns a primary genetic concept into a maddeningly addictive mobile game.
Find a Job
We're looking for smart, passionate people to join our team. Search our open positions.
How to Get Into the Brain
Learn how Genentech scientists developed a new way to get medicines through the blood-brain barrier.
From Our Labs
New research now published in Science Translational Medicine about discovering and overcoming roadblocks in crossing the blood-brain barrier. Read the publication.
Scientific Excellence Award
Vishva Dixit, VP - Physiological Chemistry, has been elected to the National Academy of Sciences, one of the highest honors given to scientists.
May 15, 2015 - Genentech's Obinutuzumab (GA101) Significantly Reduced the Risk of Disease Progression or Death in People with One of the Most Common Forms of Blood Cancer
May 14, 2015 - Genentech to Present Important New Data Reflecting Broad Cancer Pipeline at ASCO
Prescribing information, important safety information and patient resources.
Our pipeline includes over 30 new molecular entities that address serious unmet medical needs.